ChemicalBook > CAS DataBase List > XAMOTEROL HEMIFUMARATE

XAMOTEROL HEMIFUMARATE

Product Name
XAMOTEROL HEMIFUMARATE
CAS No.
81801-12-9
Chemical Name
XAMOTEROL HEMIFUMARATE
Synonyms
Xamoterolum;XAMOTEROL FUMARATE;Ixazomib Impurity 63;XAMOTEROL HEMIFUMARATE USP/EP/BP;4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-
CBNumber
CB8497497
Molecular Formula
C16H25N3O5.C4H4O4
Formula Weight
455.461
MOL File
81801-12-9.mol
More
Less

XAMOTEROL HEMIFUMARATE Property

Melting point:
168-170°C
solubility 
H2O: 10 mg/mL at 60 °C, soluble
form 
solid
color 
white
More
Less

Safety

Safety Statements 
22-24/25
WGK Germany 
3
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
BRS0000819
Product name
XAMOTEROL
Purity
95.00%
Packaging
5MG
Price
$503.43
Updated
2021/12/16
Medical Isotopes, Inc.
Product number
42627
Product name
Xamoterol
Packaging
10mg
Price
$650
Updated
2021/12/16
American Custom Chemicals Corporation
Product number
BRS0000819
Product name
XAMOTEROL
Purity
95.00%
Packaging
25MG
Price
$1501.96
Updated
2021/12/16
More
Less

XAMOTEROL HEMIFUMARATE Chemical Properties,Usage,Production

Originator

Sepan,Yamanouchi

Uses

Stimulant (cardiac).

Uses

Xamoterol is an authentic β1-adrenoceptor (β1-AR) agonist that has been shown to mimic the autoantibody effect on rat atria β1-AR apoptosis.

Definition

ChEBI: Xamoterol is a member of morpholines.

Manufacturing Process

A suspension of 1-p-benzyloxyphenoxy-2,3-epoxypropane (11.5 g) in isopropanol (6 ml) is added to a stirred mixture of 4-(N-beta- aminoethylcarbamoyl) morpholine hydrogen sulphate (12.7 g), potassium hydroxide (7.0 g) and isopropanol (10 ml) and the mixture is stirred at 45°C for 1 hour and then evaporated to dryness under reduced pressure. The residual oil is stirred with water, the mixture is filtered and the solid residue is dissolved in acetone. A 30% solution of hydrogen chloride in propanol is added until the pH of the mixture is less than 2, and the mixture is filtered. The solid residue is crystallised from water and there is thus obtained 1-p- benzyloxyphenoxy-3-(beta-morpholinocarbonamidoethyl)amino-2-propanol hydrochloride (4.9 g).
A solution of the above compound in a mixture of ethanol (20 ml) and acetic acid (20 ml) is shaken with a 30% palladium-on-charcoal catalyst (0.1 g) in an atmosphere of hydrogen at laboratory temperature and pressure until 250 ml of hydrogen is absorbed. The mixture is filtered, the filtrate is evaporated to dryness under reduced pressure and to the residue is added a hot solution of fumaric acid (1.25 g) in ethanol (15 ml). The mixture is kept at 5°C for 12 hours and is then filtered, and the solid residue is washed with hot ethanol and then dried. There is thus obtained 1-p-hydroxyphenoxy-3-beta- (morpholinocarbonamido)ethyl-amino-2-propanol hydrogen fumarate, m.p. 168-169°C (with decomposition).
The 4-(N-beta-aminoethylcarbamoyl)morpholine hydrogen sulphate used as starting material may be obtained as follows:
Morpholine (4.35 g) and phenyl chloroformate (6.35 g) are separately and simultaneously added dropwise during 20 min to a stirred mixture of toluene (10 ml), water (5 ml) and sodium hydroxide (2 g) which is maintained at 0°C. The mixture is stirred for a further 2 hours whilst the temperature is allowed to rise to 20°C. The toluene solution is separated, the aqueous solution is extracted twice with toluene and the combined toluene solutions are washed with water, dried and evaporated to dryness under reduced pressure. The residue is crystallised from petroleum ether (boiling point 60-80°C) and there is thus obtained N-phenoxycarbonylmorpholine, melting point 46.5-47.5°C.
A mixture of the above compound (11 g) and ethylenediamine (27.8 g) is stirred at laboratory temperature for 3 days and the excess of ethylene diamine is removed by evaporation under reduced pressure. The residue is dissolved in methanol, the solution is cooled to 5°C and concentrated sulfuric acid is added until the pH of the solution is 2. A filter-aid (Celite, 10 g) is added and the mixture is stirred for 1 hour and then filtered. The filtrate is evaporated to dryness under reduced pressure and the residue is stirred with ethyl acetate. The mixture is filtered and there is thus obtained as solid residue 4-(N-beta-aminoethylcarbamoyl)morpholine hydrogen sulphate, melting point 168-169°C.

Therapeutic Function

Beta-adrenergic blocker, Cardiac stimulant

XAMOTEROL HEMIFUMARATE Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

XAMOTEROL HEMIFUMARATE Suppliers

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
Tianjin Kailiqi Biotechnology Co., Ltd.
Tel
15076683720
Fax
022-23754520
Email
klq@cw-bio.com
Country
China
ProdList
4602
Advantage
55
Hubei Yangxin Medical Technology Co., Ltd.
Tel
15374522761
Fax
QQ:2853117752
Email
3003392093@qq.com
Country
China
ProdList
8377
Advantage
55
Shenzhen Polymeri Biochemical Technology Co., Ltd.
Tel
+86-400-002-6226 +86-13028896684;
Email
sales@rrkchem.com
Country
China
ProdList
57412
Advantage
58
Shaanxi Dideu Medichem Co. Ltd
Tel
+86-029-89586680 +86-18192503167
Fax
+86-29-88380327
Email
1026@dideu.com
Country
China
ProdList
7724
Advantage
58
Energy Chemical
Tel
021-58432009 400-005-6266
Fax
021-58436166
Email
marketing@energy-chemical.com
Country
China
ProdList
44918
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24647
Advantage
58
Nanjing Shizhou Biology Technology Co.,Ltd
Tel
025-85560043 15850508050
Fax
025-85563444
Email
cindy.huang@synzest.com
Country
China
ProdList
12005
Advantage
58
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19885
Advantage
58

81801-12-9, XAMOTEROL HEMIFUMARATERelated Search:


  • XAMOTEROL FUMARATE
  • 4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-
  • XAMOTEROL HEMIFUMARATE USP/EP/BP
  • Xamoterolum
  • Ixazomib Impurity 63
  • 81801-12-9
  • C16H25N3O5